



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/395, 38/19	A1	(11) International Publication Number: WO 00/40265 (43) International Publication Date: 13 July 2000 (13.07.00)
(21) International Application Number: PCT/US00/00528 (22) International Filing Date: 7 January 2000 (07.01.00) (30) Priority Data: 09/226,895 7 January 1999 (07.01.99) US (71) Applicant: RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street, Carson City, NV 89703 (US). (72) Inventors: ROSENBLUM, Michael, G.; 3127 Stoney Mist Drive, Sugar Land, TX 77479 (US). MEHTA, Kapil; 4505 Maple, Bellaire, TX 77401 (US). (74) Agent: WEILER, James, F.; 1 Riverway, Suite 1560, Houston, TX 77056 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: POTENTIATION OF ANTI-CD38-IMMUNOTOXIN CYTOTOXICITY (57) Abstract <p>The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-<i>trans</i>-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

POTENTIATION OF ANTI-CD38-IMMUNOTOXIN CYTOTOXICITY

5

BACKGROUND OF THE INVENTION

10

Field of the Invention

The present invention relates generally to the fields of immunology and tumor biology. More specifically, the present invention relates to treatment for the enhancement of CD38 protein expression in target tumor cells to increase the cytotoxicity of anti-CD38 based immunotoxins.

Description of the Related Art

The use of monoclonal antibodies for delivering drugs or toxins to distinct molecular structures expressed on the surface of unwanted tumor cells represents an attractive and potentially useful strategy. Theoretically, such a targeted approach to cancer therapy could offer a major advance in the selective elimination of tumor cells while reducing the toxicity of treatment towards normal non-target tissues. Nevertheless, in practice many problems exist that need to be addressed before immunotoxin or antibody-drug therapies can be truly effective *in vivo*.

One potential limitation to the success of any targeted approach to therapy is the heterogeneity of target antigen

expression within a population of tumor cells. It follows that if a small number of cells within a tumor were negative for the target antigen or expressed the antigen only very weakly, then these cells could possibly escape destruction due to a failure of antibody-mediated delivery of the cytotoxic agent to those particular cells. A possible means of overcoming this problem would be to identify agents that induce high levels of cell surface target molecules, in the expectation that target tumor cells which were antigen negative would express these target molecules in abundance.

All-*trans*-retinoic acid (RA) is an agent that induces high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. Retinoic acid-induced expression of CD38 in these cells is specific, rapid, dose-dependent, and highly sensitive, with 4-fold induction at as low a dose of retinoic acid as 10^{-13} M. The induction of CD38 expression by retinoic acids has been shown to involve the RAR α retinoid receptor. RAR receptors form heterodimers with RXR receptors; the RXR/RAR heterodimer then interacts with DNA sequences known as retinoic acid response elements (RARE's) which are involved in retinoid-induced transcription.

CD38 is a 45-kDa cell surface protein which is primarily expressed by early progenitor and mature activated cells of the hematopoietic system. It is a transmembrane glycoprotein with a short N-terminal cytoplasmic domain and a long C-terminal extracellular domain. The extracellular domain has been shown to be a bifunctional enzyme having ADP-ribosyl cyclase as well as ADP-ribosyl hydrolase activities in that it catalyzes the conversion of NAD⁺ to cADPR (cyclase) and can further hydrolyze it to ADP-ribose (hydrolase). cADPR is involved in the mobilization of calcium from intracellular stores which is a second messenger activity important for cellular proliferation, differentiation, and apoptosis. CD38 is believed

to act as a receptor for an unidentified ligand and to act as a cell adhesion molecule by interacting with CD31. Experiments in which CD38 function was activated by monoclonal antibodies directed against it have implicated CD38 in proliferation of mature B lymphocytes and myeloid leukemia cells, rescue of germinal center cells from apoptosis, and growth suppression of stroma-supported cultures of B-cell progenitors as well as induction of the cytokines IL-6, IL-1, IL-8, GM-CSF, and IL-10. In addition, it has been shown to signal an increase in TNF- α , IL-1, IL-6, and IL-8 transcription in myeloid leukemia cells.

The prior art is deficient in the lack of a method to induce the expression of a target molecule for immunotherapy of tumor and other disease-causing cells. The present invention fulfills this longstanding need and desire in the art.

SUMMARY OF THE INVENTION

The present invention demonstrates the potential of retinoid-induced CD38 expression to serve as a target for delivering the immunotoxin anti-CD38-gelolin. The results obtained suggested that retinoic acid treatment of leukemia cells, even at very low concentrations (subnanomolar) makes these cells exquisitely sensitive to immunotoxin-induced killing.

The current invention comprises a method of treating an individual having a pathophysiological state, comprising the step of administering to said individual a pharmacologically effective dose of an agent which upregulates the expression of a cellular target and also administering a pharmacologically effective dose of an immunotoxin directed against the upregulated cellular target.

The current invention also comprises a method of treating an individual having a pathophysiological state responsive to retinoid treatment, comprising the step of administering to said individual a pharmacologically effective dose of a retinoic acid metabolite and a
5 pharmacologically effective dose of an immunotoxin.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.

10

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features,
15 advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of
20 the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

Figure 1 shows a dot blot of mRNA from a variety of human tissues after hybridization with a radiolabeled human CD38-specific nucleic acid probe. Relatively low CD38 mRNA expression was
25 observed only in thymus tissue [from both adult (E5) and fetal (G6)] while a lesser level of expression was seen in normal prostate (C7).

Figure 2 shows the effects of 5 nM all-*trans*-retinoic acid (RA) on the cytotoxicity of the immunotoxin and

the effects of adding increasing concentrations of the unconjugated anti-CD38 monoclonal antibody (IB4). Point C indicates the effect of immunotoxin alone. +IT (+RA) shows the effect of 5 nM all-*trans*-retinoic acid (RA) on the cytotoxicity of the immunotoxin. In the rest of the samples, increasing concentrations of IB4 were added along with immunotoxin and 5 nM all-*trans*-retinoic acid (RA). After 3 days of incubation, cell viability was determined with the MTS assay. The results are represented in terms of % surviving cells.

Figure 3 shows effect of retinoic acid pretreatment on the cytotoxicity of anti-CD38 immunotoxin on HL-60 cells. HL-60 cells were incubated overnight in the presence or absence of retinoic acid. After removal of the media and twice washing the cells, the cells were reincubated with increasing concentrations of immunotoxin (represented as ng/well) in the presence or absence of 100-fold excess of unconjugated anti-CD38 monoclonal antibody IB4. After three days, the MTS assay was used to determine cell viability which is represented in terms of % surviving cells.

Figure 4 shows the effect of treatment with either immunotoxin or gelonin on the viability of HL-60 cells. HL-60 cells were incubated for three days in increasing concentrations of either immunotoxin or gelonin (represented as ng/well toxin) in the presence or absence of 5 nM retinoic acid. Cell viability was determined by the MTS assay and is represented here in terms of percent cell survival relative to the control sample (no toxin).

Figure 5 shows the effect of increasing concentrations of all-*trans*-retinoic acid (RA) (in nM) on cell survival. HL-60 cells were incubated with either immunotoxin or unconjugated anti-CD38 monoclonal antibody in either the absence or the presence of increasing concentration of retinoic acid (shown in nM). After

three days, cell viability was determined by MTS assay and is shown in terms of percentage of cell survival relative to an untreated control.

Figures 6A and 6B show the effect of increasing concentrations of immunotoxin (shown in ng/well) in either the presence or absence of 5 nM all-*trans*-retinoic acid (RA) on cell survival of different cell lines including Daudi, THP-1, K562 (which is resistant to RA-induced expression of CD38), and a RAR α -expressing variant of HL60. Cell viability was measured by the MTS assay after three days and is represented in terms of percent cell survival relative to an untreated control.

Figure 7 shows the immunotoxin induced killing of Doxo-resistant HL-60 cells which are resistant to adriamycin-induced killing. The cells were incubated with increasing concentrations of immunotoxin (shown in ng/well) in either the presence or absence of 5 nM RA. Cell survival was assayed after 3 days using the MTS assay.

Figure 8 shows the immunotoxin mediated killing of the non-Hodgkin lymphoma cell line MZ(NHL) that has a high basal expression of CD38 antigen. The cell were incubated with increasing concentrations of immunotoxin (shown in ng/well) in the presence or absence of 5 nM retinoic acid. After three days, cell viability was assayed with the MTS assay and is shown in terms of % viable cells.

Figure 9 shows the immunotoxin mediated killing of the retinoic acid-resistant variant of the HL60 cell line (HL60R). These cells are resistant to retinoic acid-induced expression of the CD38 antigen due to a point mutation in the retinoic acid receptor alpha (RAR α) gene. The cell line was cultured with increasing concentrations of immunotoxin (in ng/ml) under different conditions. After 3 days, cell viability was assayed by the MTS assay and is represented in terms of O.D. The presence of retinoic acid failed to promote

immunotoxin-induced killing of these cells due to their inability to express CD38 antigen in response to retinoic acid treatment.

5 DETAILED DESCRIPTION OF THE INVENTION

An immunotoxin is defined as any immunological molecule such as an antibody which has been conjugated with a toxin, preferably a cytotoxin.

10 The present invention is directed to a method of treating an individual having a pathophysiological state, comprising the step of administering to said individual an a pharmacologically effective dose of an agent which upregulates the expression of a cellular target. This administration is followed by the administration of a pharmacologically
15 effective dose of an immunotoxin directed against the cellular target. Preferably, the administered agent is selected from the group consisting of differentiating agents, cytokines, interleukin-2, tumor necrosis factor, interferon- α , interferon- γ and peptide hormones.

In one embodiment, the invention comprises the
20 administration of a pharmacologically effective dose of a retinoid. Preferably, the retinoid induces expression of CD38 antigen in cells. If this is the case, a pharmacologically effective dose of an anti-CD38 immunotoxin is administered. Representative pathophysiological states which may be treated using the methods of this embodiment of the
25 invention include RAR α selective acute myeloid leukemia, acute promyelocytic leukemia, lymphomas, and myelomas.

Representative retinoic acid metabolites which may be used in the methods of the present invention include all-*trans*-retinoic acid (RA); 9-*cis* retinoic acid (9-*cis* RA); (*E*)-4-[2-

(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); (*E*)-4-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-propenyl]benzoic acid (3-met TTNPB); and other retinoids that can bind and activate the RAR α receptor.

5 Preferably, the retinoid is administered in a dose of from about 0.1 mg/kg to about 2 mg/kg.

The immunotoxin used in the methods of the present invention specifically target cells expressing the CD38 antigen. Preferably, the immunotoxin comprises a monoclonal antibody directed
10 against the CD38 antigen conjugated to a toxin molecule. Although a person having ordinary skill in this art could substitute any toxin, a preferred toxin useful in these methods is gelonin. Although a person having ordinary skill in this art could substitute any monoclonal antibody specific for the CD38 antigen, IB4 or IB6 antibodies were used
15 herein to demonstrate the present methods. Preferably, the immunotoxin is administered in a dose of from about 0.05 mg/kg to about 2 mg/kg.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to
20 limit the present invention in any fashion.

EXAMPLE 1

CD38 expression in normal tissues is limited mainly to the thymus.

25 The tissue specificity of CD38 was examined by the hybridization of a radiolabeled CD38 nucleic acid probe against a commercial (CLONTECH) tissue specific mRNA dot blot. The results of the hybridization are shown in Figure 1. It was observed that CD38 is mainly expressed in the thymus with significantly lower levels
30 of expression in the prostate.

EXAMPLE 2

Retinoic acid (RA) augments the cytotoxic effect of immunotoxin through enhanced expression of CD38.

5 HL-60 cells were incubated with either immunotoxin alone or in the presence of 5 nM retinoic acid (RA). Increasing concentrations of unconjugated IB4 monoclonal antibody were added to the cells incubated with immunotoxin and retinoic acid. After three days, the cells were assayed for viability with the MTS assay. Briefly,
10 6.5 mg/ml MTS solution [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and 0.5 mM PMS (phenazine methosulfate) solution were mixed at a ratio of 20:1. 20 μ l of the combined MTS/PMS solution was placed in each well of a 96 well plate containing samples of the cells to be tested. The
15 plate was incubated for 1-4 hours at 37°C in a 5% CO₂ atmosphere, after which time, the amount of formazan produced by live cells from cellular reduction of MTS was measured by reading the absorbance at 490 nm. The results are shown in Figure 2.

Immunotoxin alone had little effect on the viability of the
20 cells (C). However, when the cells were incubated with immunotoxin in the presence of 5 nM retinoic acid, a significant reduction in cell viability was observed. Increasing concentrations of unconjugated IB4 monoclonal antibody blocked the cytotoxic effect of immunotoxin and retinoic acid. The fact that unconjugated IB4 blocked the ability of the
25 immunotoxin to kill the cells demonstrates that the immunotoxin is specifically interacting with the CD38 surface marker and that the effect of the retinoic acid is to increase the expression of the CD38 antigen.

EXAMPLE 3

All-*trans*-retinoic acid (RA) pretreatment enhances the induced killing of HL-60 Cells.

5 HL-60 cells were preincubated overnight in either the presence or absence of 5 nM all-*trans*-retinoic acid. The cells were washed twice and incubated in increasing concentrations of immunotoxin in either the presence or absence of IB4 unconjugated anti-CD38 MoAb. After three days, the cell were assayed for viability.
10 The results are shown in Figure 3.

 Preincubation with all-*trans*-retinoic acid followed by immunotoxin treatment resulted in more cell death than treatment with immunotoxin alone. The presence of 100 fold excess of the unconjugated anti-CD38 monoclonal antibody IB4 blocked the toxicity
15 of the immunotoxin in both cases by competing with the immunotoxin for access to the CD38 markers on the cells. These results demonstrate that the all-*trans*-retinoic acid (RA) was causing some change in the cells which render them more susceptible to the immunotoxin rather than playing a direct role in the death of the target cells.

20

EXAMPLE 4

Gelonin must be conjugated to the anti-CD38 antibody to have a toxic effect on the target cells.

25 HL-60 cells were incubated for three days with increasing concentrations of either immunotoxin or gelonin in either the presence or absence of 5 nM retinoic acid. Afterwards, the cells were assayed for viability using the MTS assay. As seen in Figure 4, gelonin alone had no toxic effect in either the presence or absence of 5
30 nM. Thus, the toxic effect of gelonin depends on it being conjugated to

the anti-CD38 monoclonal antibody in order to deliver the toxin to the cell.

EXAMPLE 5

5

Even nominal levels of all-*trans*-retinoic acid (RA) lead to increased toxicity of the immunotoxin.

HL-60 were incubated with either immunotoxin or unconjugated IB4 monoclonal antibody in increasing concentrations of monoclonal antibody. Figure 5 shows that even the lowest level of all-*trans*-retinoic acid (RA) (1 nM) lead to almost complete killing of the target cells by the immunotoxin. This effect was not observed with the unconjugated monoclonal antibody. This result indicates that it is the gelonin conjugated to the monoclonal antibody in the immunotoxin that leads to the increased cell death rather than some effect of the antibody itself.

EXAMPLE 6

20 Retinoic acid can induce expression of the CD38 marker in a variety of cell lines.

The Daudi, THP-1, K562, and HL60-RAR α cell lines were treated with increasing concentrations of immunotoxin in either the presence or absence of 5 nM all-*trans*-retinoic acid (RA). After three days, the viability of the cells was examined using the MTS assay, which is shown in Figure 6. In the THP-1 and HL60-RAR α cell lines, all-*trans*-retinoic acid induced cell death while the cell which were cultured in the absence of all-*trans*-retinoic acid were mostly unaffected by the immunotoxin. In the Daudi cells, which have a high basal

expression of CD38, the immunotoxin resulted in almost complete cell death regardless of whether retinoic acid was present. On the other hand, K562, which are resistant to RA-induced CD38 expression, were unaffected by the immunotoxin regardless of the presence of retinoic acid.

EXAMPLE 7

Immunotoxin induced cell death in HL-60 cells resistant to Adriamycin.

HL-60 subcloned cells, resistant to adriamycin-induced killing were cultured with immunotoxin either alone or in the presence of 5 nM all-*trans*-retinoic acid. After three days, the MTS assay was used to test cell viability. Figure 7 shows the results obtained. Some cell death was observed in the presence of immunotoxin alone which was greatly augmented by the addition of 5 nM all-*trans*-retinoic acid.

EXAMPLE 8

Cells which have high basal expression of CD38 are killed by immunotoxin regardless of the presence or absence of all-*trans*-retinoic acid (RA).

MZ, a non-Hodgkin lymphoma cell line which has a high basal expression of CD38, was treated with increasing amounts of immunotoxin in either the presence or absence of 5 nM all-*trans*-retinoic acid. The addition of immunotoxin resulted in a high level of cell death regardless of the presence or absence of retinoic acid (Figure 8). This is strong evidence that retinoic acid is increasing the toxicity of immunotoxin by enhancing the level of CD38 on other cell lines which do not have a high basal level of CD38.

EXAMPLE 9

Retinoic increases CD38 expression in a number of lymphoid tumor cells.

5 Table I lists the potential targets for anti-CD38 bound toxin treatment. A number of different lymphoid tumor cell lines were treated with 5 nM all-*trans*-retinoic acid (RA). Afterwards, the expression of CD38 in untreated versus treated cell was measured by flow cytometry. A significant rise in CD38 expression was observed in
10 acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), lymphoma, and myeloma tumor cells. The increase in CD38 expression ranges from 2.5 to 20 fold. Thus, retinoic acid can be used in all of these tumor types to increase the vulnerability of the tumor cells to immunotoxin treatment.

15

TABLE 1

Potential Targets for Anti-CD38 Bound Toxin Treatment

Cell Target	Basal CD38	CD38 after RA Treatment
AML	50 ± 10	180 ± 20
APL	6 ± 4	120 ± 30
Lymphomas	80 ± 20	210 ± 10
Myelomas	60 ± 20	180 ± 25
SLE	B cells producing self reactive ab Self reactive T lymphocyte	
Myesthenia gravis		
Rheumatoid arthritis		
Organ transplantation		

30

EXAMPLE 10

Immunotoxin does not affect cells resistant to all-*trans*-retinoic acid (RA)

5 HL-60 cells with a mutated RAR α gene that renders the cells resistant to the effects of retinoic acid were treated with immunotoxin in either the presence or absence of 5 nM retinoic acid. In these cells, the addition of retinoic acid had no effect on the toxicity of the immunotoxin. As shown in Figure 9, no appreciable cell death was
10 observed in the cells treated with all-*trans*-retinoic acid (RA), with unconjugated IB4 and gelonin, or with gelonin alone. This is further proof that the immunotoxin kills cells which are affected by retinoic acid because of a retinoid induced increase in expression of CD38 target of the immunotoxin.

15 Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual
20 publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The
25 present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which

are encompassed within the spirit of the invention as defined by the scope of the claims.

WHAT IS CLAIMED IS:

1. A method of treating an individual having a pathophysiological state, comprising the steps of:

5 a). administering to said individual a pharmacologically effective dose of a agent which up-regulates the expression of a cellular target; and,

b). administering to the same individual a pharmacologically effective dose of an immunotoxin directed against
10 the up-regulated cellular target.

2. The method of claim 1, wherein the administered agent is selected from the group consisting of differentiating agents,
15 cytokines, interleukin-2, tumor necrosis factor, interferon- α , interferon- γ and peptide hormones.

3. The method of claim 1, wherein said agent is a
20 retinoid and wherein said cell target is the CD38 antigen.

4. The method of claim 3, wherein said pathophysiological state is selected from the group consisting of acute
25 myeloid leukemia, acute promyelocytic leukemia, lymphomas, and myelomas.

5. The method of claim 3, wherein said

retinoid is selected from the group consisting of all-*trans*-retinoic acid (RA); 9-*cis* retinoic acid (9-*cis* RA); (*E*)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); (*E*)-4-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-propenyl]benzoic acid (3-met TTNPB).

6. The method of claim 5, wherein said retinoid is administered in a dose of from about 0.1 mg/kg to about 2 mg/kg.


7. The method of claim 3, wherein said immunotoxin specifically targets cells expressing the CD38 antigen.

8. The method of claim 7, wherein said immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule.

9. The method of claim 8, wherein said toxin is gelonin.

10. The method of claim 8, wherein the monoclonal antibody is selected from the group consisting of IB4 or IB6.

11. The method of claim 1, wherein said immunotoxin is administered in a dose of from about 0.05 mg/kg to about 2 mg/kg.

**Fig. 1**




Fig. 2





Fig. 3







Fig. 6A




Fig. 6B




Fig. 8




Fig. 7




Fig. 9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/00528

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/395, 38/19

US CL : 424/183.1, 85.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/183.1, 85.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST and Biosis on STN

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MEREDITH et al. Phase II study of dual 131 I-labeled monoclonal antibody therapy with interferon in patients with metastatic colon cancer. Clinical Cancer Research. November 1996, Vol.2, pages 1811-1818, especially page 1812 and table 2 on page 1814.	1-2
-		----
Y		11
Y	MEHTA et al. Retinoic acid-induced CD38 cell surface protein as a target for immunotoxin therapy: in vitro evaluation. Proceedings of the American Association for Cancer Research. March 1997, Vol.38, page 88, see entire document.	1-4, 6-10

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* & * document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 FEBRUARY 2000

Date of mailing of the international search report

06 APR 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Karen A. Canella

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/00528

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HIROTA et al. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Research. 15 December 1989, Vol.49, pages 7106-7109, see entire document.	1-3, 7-10
Y	MEHTA et al. Induction of CD38 by retinoic acid in myeloid leukemia cells. Proceedings of the American Association for Cancer Research. March 1994, Vol.35, page 92, see entire document.	4-6
Y	HANK et al. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer. Clinical Cancer Research. May 1995, Vol.1, pages 481-491, see entire document.	11